Xieqiao Yan

机构：Peking University, Peking University Cancer Hospital, Ministry of Education · ORCID：0000-0002-1781-3193

发表论文 185 篇 · 总被引 2732 次 · h-index 28

代表论文

• Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study (2024 · Annals of Oncology · 被引 56)
• Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial (2024 · Signal Transduction and Targeted Therapy · 被引 38)
• Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights (2025 · Journal for ImmunoTherapy of Cancer · 被引 22)
• Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study (2025 · Med · 被引 16)
• Dynamic Change of PD‐L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti‐PD‐1 Therapy (2025 · Journal of Extracellular Vesicles · 被引 8)
• MARCO+ Tumor‐Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma (2025 · Advanced Science · 被引 6)